Clinical Trials
14 trialsNCT05985187 2023-08-14
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT05720026 2023-02-09
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT03863223 2022-11-23
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05346861 2022-04-26
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Phase 3 Unknown
NCT04385563 2020-05-13
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT04337658 2020-04-08
FAVOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Unknown
NCT01104571 2018-09-17
EPHOS-B
Institute of Cancer Research, United Kingdom
Phase 3 Unknown
NCT03006614 2017-01-16
PERS
Sun Yat-sen University
Phase 3 Unknown
NCT00486668 2016-06-06
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Phase 3 Unknown
NCT00629278 2013-08-07
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00712140 2011-09-02
Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00430001 2008-05-09
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
Danish Breast Cancer Cooperative Group
Phase 3 Unknown
NCT00637325 2008-03-17
TOP
Regione Lombardia
Phase 3 Unknown